Quantification of Outcome Measures for Mind-body Interventions

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
John W. Denninger, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01308970
First received: February 24, 2011
Last updated: March 30, 2015
Last verified: March 2015
  Purpose

The purpose of this study is to determine if participation in one of three different health management groups will elicit genomic and biochemical changes and decrease perceived stress levels and symptoms in healthy, stressed adults. The investigators expect that changes in self-reported psychological stress and symptoms will be directly linked to changes in biological indicators (genomic expression profiles and neuroendocrine and pro-inflammatory biomarkers).


Condition Intervention
Stress, Psychological
Stress, Physiological
Behavioral: Stress Management Group 1
Behavioral: Stress Management Group 2
Behavioral: Stress Management Group 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Official Title: Quantification of Outcome Measures for Mind-body Interventions

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Change in Perceived Stress Levels Post-intervention and at 6-month Follow-up [ Time Frame: Baseline (Week 1), Endpoint (Week 9), Follow-Up (Week 26) ] [ Designated as safety issue: No ]
    Perceived Stress Scale (PSS-10)

  • Change in Genomic Expression Profile Post-intervention and at 6-month Follow-up [ Time Frame: Baseline (Week 1), Endpoint (Week 9), Follow-Up (Week 26) ] [ Designated as safety issue: No ]

Estimated Enrollment: 450
Study Start Date: March 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stress Management Group 1 Behavioral: Stress Management Group 1
Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Experimental: Stress Management Group 2 Behavioral: Stress Management Group 2
Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Experimental: Stress Management Group 3 Behavioral: Stress Management Group 3
Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.

Detailed Description:

This randomized, controlled trial will determine the relative strength of correlation between changes in stress outcome measures (self-report questionnaire, genomic expression, biochemical assay) in moderately to severely stressed healthy subjects randomized to one of three health education interventions at both end-intervention and at a 6-month long-term follow-up. This study will also determine which of the different outcome measures exhibit the greatest degree of sensitivity, reliability and consistency at both end-intervention and long-term follow-up.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18 or older
  • Stress is chronic and ongoing with no resolution of the stressors within the timeframe of the study, with a minimum prior duration of 6 months.
  • Able to provide informed consent and to understand written and spoken English.

Exclusion Criteria:

  • Practice of yoga, meditation, guided imagery or other mind body techniques that elicit the RR, once per week for 45 min total or more within the last three months or less.
  • Any current medical condition that would preclude their safe and effective practice of the yoga or meditation interventions.
  • The presence of bipolar or psychotic disorders, or history of any other DSMIV Axis I disorder with active symptoms or treatment within the last 5 years, as determined by a structured clinical interview.
  • Initiation of psychotherapy within 6 months of entering the study.
  • Serious or unstable medical illness, including serious or unstable cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease.
  • Patient deemed unable to complete protocol due to cognitive, psychiatric or other reasons.
  • Pregnancy or planned conception over the course of the study (could confound biomarker values).
  • Current use of the following medications: systemic corticosteroids, chronic (i.e., more than 3 days per week) use of anti-inflammatories (e.g., ibuprofen; currently or within the last 3 months), immunosuppressive or cytotoxic therapies (currently or within the last 12 months), and anabolic steroids.
  • Current (within the last 6 months) psychoactive medications (e.g. antidepressants, mood stabilizers, antipsychotics, anxiolytics), with the exception of hypnotics, which will be permitted.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01308970

Locations
United States, Massachusetts
Benson-Henry Institute for Mind Body Medicine; Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: John W Denninger, MD, PhD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: John W. Denninger, MD, PhD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01308970     History of Changes
Other Study ID Numbers: 2010P002785, R01AT006464
Study First Received: February 24, 2011
Last Updated: March 30, 2015
Health Authority: United States: Institutional Review Board
United States: Federal Government

Additional relevant MeSH terms:
Stress, Psychological
Behavioral Symptoms

ClinicalTrials.gov processed this record on May 05, 2015